210 related articles for article (PubMed ID: 20164240)
21. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.
Ammoun S; Cunliffe CH; Allen JC; Chiriboga L; Giancotti FG; Zagzag D; Hanemann CO; Karajannis MA
Neuro Oncol; 2010 Aug; 12(8):834-43. PubMed ID: 20511180
[TBL] [Abstract][Full Text] [Related]
22. Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.
Han S; Polizzano C; Nielsen GP; Hornicek FJ; Rosenberg AE; Ramesh V
Clin Cancer Res; 2009 Mar; 15(6):1940-6. PubMed ID: 19276265
[TBL] [Abstract][Full Text] [Related]
23. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
[TBL] [Abstract][Full Text] [Related]
24. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
Dewaele B; Floris G; Finalet-Ferreiro J; Fletcher CD; Coindre JM; Guillou L; Hogendoorn PC; Wozniak A; Vanspauwen V; Schöffski P; Marynen P; Vandenberghe P; Sciot R; Debiec-Rychter M
Cancer Res; 2010 Sep; 70(18):7304-14. PubMed ID: 20685895
[TBL] [Abstract][Full Text] [Related]
25. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors.
Dobashi Y; Suzuki S; Sugawara H; Ooi A
Hum Pathol; 2007 Jun; 38(6):914-25. PubMed ID: 17376509
[TBL] [Abstract][Full Text] [Related]
26. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.
Presneau N; Shalaby A; Idowu B; Gikas P; Cannon SR; Gout I; Diss T; Tirabosco R; Flanagan AM
Br J Cancer; 2009 May; 100(9):1406-14. PubMed ID: 19401700
[TBL] [Abstract][Full Text] [Related]
27. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
28. Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression.
Walter BA; Begnami M; Valera VA; Santi M; Rushing EJ; Quezado M
J Neurooncol; 2011 Jan; 101(2):199-206. PubMed ID: 20617367
[TBL] [Abstract][Full Text] [Related]
29. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
[TBL] [Abstract][Full Text] [Related]
30. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.
Bozzi F; Manenti G; Conca E; Stacchiotti S; Messina A; Dagrada G; Gronchi A; Panizza P; Pierotti MA; Tamborini E; Pilotti S
Neuro Oncol; 2014 Jan; 16(1):72-80. PubMed ID: 24366975
[TBL] [Abstract][Full Text] [Related]
31. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
32. Analysis of clinical factors and PDGFR-β in predicting prognosis of patients with clival chordoma.
Zhai Y; Bai J; Wang S; Gao H; Li M; Li C; Gui S; Zhang Y
J Neurosurg; 2018 Dec; 129(6):1429-1437. PubMed ID: 29303447
[TBL] [Abstract][Full Text] [Related]
33. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
Matsumura I; Mizuki M; Kanakura Y
Cancer Sci; 2008 Mar; 99(3):479-85. PubMed ID: 18177485
[TBL] [Abstract][Full Text] [Related]
34. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
[TBL] [Abstract][Full Text] [Related]
35. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
36. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
37. Conserved roles for receptor tyrosine kinase extracellular regions in regulating receptor and pathway activity.
Gonzalez-Magaldi M; McCabe JM; Cartwright HN; Sun N; Leahy DJ
Biochem J; 2020 Nov; 477(21):4207-4220. PubMed ID: 33043983
[TBL] [Abstract][Full Text] [Related]
38. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors.
Bozzi F; Tamborini E; Negri T; Pastore E; Ferrari A; Luksch R; Casanova M; Pierotti MA; Bellani FF; Pilotti S
Cancer; 2007 Apr; 109(8):1638-45. PubMed ID: 17342771
[TBL] [Abstract][Full Text] [Related]
39. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
40. Differences in Dural Penetration of Clival Chordomas Are Associated with Different Prognosis and Expression of Platelet-Derived Growth Factor Receptor-β.
Zhai Y; Bai J; Wang S; Du J; Wang J; Li C; Gui S; Zhang Y
World Neurosurg; 2017 Feb; 98():288-295. PubMed ID: 27506406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
